Clinical Study

Ea6141- Phase II/III Trial Of Nivolumab, Ipilimumab, And Gm-Csf In Patients With Advanced Melanoma

Posted Date: Oct 5, 2020

  • Investigator: Rekha Chaudhary
  • Specialties: Dermatology, Oncology, Skin Cancer
  • Type of Study: Drug

This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.


Patient's With Advanced Newly Diagnosed (Unresectable) Melanoma Will Be Eligible


Advanced Melanoma, Nivolumab, Ipilimumab

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.